The four-pronged strategy begins with the acquisition of GSK's oncology portfolio, which includes all of its marketed products and late-stage candidates, for $14.5 billion, with a further $1.5 ...
Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...
NEW YORK CITY, NY / ACCESS Newswire / March 11, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...
Clinical Trials Arena on MSN10d
GSK reports positive outcomes from two Phase III trials of treatment for CRSwNPSecondary endpoint analyses from the trials showed 'significant improvements' in patients treated with the antibody.
We recently published a list of the 10 Best Vaccine Stocks to Buy According to Hedge Funds. In this article, we are going to ...
GSK's revenue and EPS exceeded my expectations and those of analysts, thanks to the strong performance of its oncology and HIV franchises. So, Ojjaara/Omjjara sales amounted to $150 million in the ...
To join the GSK class action, go to https://rosenlegal.com/submit-form/?case_id=34609 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class ...
Two recent high-profile acquisitions exemplify this trend; Eli Lilly’s pursuit of Scorpion Therapeutics and GSK’s acquisition of IDRx. Eli Lilly’s Bold Bid to Lead Oncology Eli Lilly’s ...
GSK reported core earnings of 59 cents per American ... Sales grew in double digits in HIV, Immunology/Respiratory as well as Oncology segments. HIV sales rose 14% driven by strong demand and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback